keyword
MENU ▼
Read by QxMD icon Read
search

psoriasis treatment

keyword
https://www.readbyqxmd.com/read/28925560/apremilast-in-psoriasis-a-prospective-real-world-study
#1
I Vujic, R Herman, M Sanlorenzo, C Posch, B Monshi, K Rappersberger, L Richter
BACKGROUND: Apremilast is a novel oral phosphodiesterase-4 inhibitor approved for psoriasis treatment. Randomized trials have documented its efficacy and safety, but data on real-world patients are scarce. OBJECTIVES: We aim to characterize psoriasis patients treated with apremilast in a real-world setting and calculate drug survival as an important measure of efficacy and compliance. METHODS: All psoriasis patients that received apremilast between April 1(st) 2015 and January 19(th) 2017 were evaluated every 4 weeks and we documented: age, weight, height, smoking status, family history of psoriasis, joint involvement, previous treatments, psoriasis area severity index (PASI) scores, and the onset and duration of adverse events (AE)...
September 19, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28924372/il-36%C3%AE-inhibits-differentiation-and-induces-inflammation-of-keratinocyte-via-wnt-signaling-pathway-in-psoriasis
#2
Wenming Wang, Xiaoling Yu, Chao Wu, Hongzhong Jin
Psoriasis is a common inflammatory skin disease characterized by abnormal keratinocyte inflammation and differentiation that has a major impact on patients' quality of life. IL-36γ, a member of IL-36 cytokine family, is highly expressed in psoriasis and plays an important role in inflammation response and differentiation. However, the function of IL-36γ in differentiation and inflammation of keratinocyte in psoriasis has not been clearly identified. Thus, this study aimed to investigate the role of IL-36γ on differentiation and inflammation in HaCaT cells...
2017: International Journal of Medical Sciences
https://www.readbyqxmd.com/read/28921587/dimethyl-fumarate-treatment-after-traumatic-brain-injury-prevents-depletion-of-antioxidative-brain-glutathione-and-confers-neuroprotection
#3
Tobias Krämer, Theresa Grob, Lutz Menzel, Tobias Hirnet, Eva Griemert, Konstantin Radyushkin, Serge C Thal, Axel Methner, Michael K E Schaefer
Dimethyl fumarate (DMF) is an immunomodulatory therapeutic for multiple sclerosis and psoriasis with neuroprotective potential. Its mechanism of action involves activation of the antioxidant pathway regulator Nuclear factor erythroid 2-related factor 2 (Nrf2) thereby increasing synthesis of the cellular antioxidant glutathione (GSH). The objective of this study was to investigate whether post-traumatic DMF treatment is beneficial after experimental traumatic brain injury (TBI). Adult C57Bl/6 mice were subjected to controlled cortical impact followed by oral administration of DMF (80 mg/kg body weight) or vehicle at 3 h, 24 h, 48 h and 72 h after the inflicted TBI...
September 16, 2017: Journal of Neurochemistry
https://www.readbyqxmd.com/read/28921458/pharmacogenetics-and-pharmacogenomics-in-moderate-to-severe-psoriasis
#4
REVIEW
María C Ovejero-Benito, Ester Muñoz-Aceituno, Alejandra Reolid, Miriam Saiz-Rodríguez, Francisco Abad-Santos, Esteban Daudén
Pharmacogenetics is the study of variations in DNA sequence related to drug response. Moreover, the evolution of biotechnology and the sequencing of human DNA have allowed the creation of pharmacogenomics, a branch of genetics that analyzes human genes, the RNAs and proteins encoded by them, and the inter-and intra-individual variations in expression and function in relation to drug response. Pharmacogenetics and pharmacogenomics are being used to search for biomarkers that can predict response to systemic treatments, including those for moderate-to-severe psoriasis...
September 18, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28919705/new-insight-into-the-pathogenesis-of-nail-psoriasis-and-overview-of-treatment-strategies
#5
REVIEW
Alessandra Ventura, Mauro Mazzeo, Roberta Gaziano, Marco Galluzzo, Luca Bianchi, Elena Campione
Psoriasis is a chronic inflammatory disease affecting up to 3% of the general population. The prevalence of nail involvement in psoriasis patients varies between 15% and 79%. While the nails represent a small portion of the body surface area, psoriasis in these areas can have a disproportionate influence on a patient's physical and psychosocial activities. Differential diagnosis between an onychomycosis and a psoriatic nail could be challenging; nevertheless, coexistence of onychomycosis and nail psoriasis also occurs and both are common disorders in the general population...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28918452/pro-oxidant-status-and-nrf2-levels-in-psoriasis-vulgaris-skin-tissues-and-dimethyl-fumarate-treated-hacat-cells
#6
Yoon Jin Lee, Jin Ho Bae, Sang-Gue Kang, Sung Woo Cho, Dong-Il Chun, Seung Min Nam, Chul Han Kim, Hae Seon Nam, Seon Hwa Lee, Sang Han Lee, Moon Kyun Cho
Reactive oxygen species (ROS) contribute to pathogenesis of many inflammatory skin diseases, including psoriasis. The aim of this study is to compare antioxidant protein expression in psoriasis vulgaris (PV) skin tissues with that in normal skin tissues in vivo and to evaluate the effects of dimethyl fumarate (DMF), used for the treatment of psoriasis, on ROS generation and apoptosis in a human keratinocyte cell line HaCaT. Compared with normal skin tissues, PV skin tissues showed increased protein oxidation as well as down-regulation of Nrf2 and its regulatory proteins such as HO-1 and AKR1C3...
September 16, 2017: Archives of Pharmacal Research
https://www.readbyqxmd.com/read/28917574/-apparent-worsening-of-psoriasis-lesions-revealing-methotrexate-overdosage
#7
R Haber, B Baroudjian, M Battistella, M Bagot, A Petit
BACKGROUND: Methotrexate (MTX) is an antimetabolite drug used in the treatment of cancers and autoimmune diseases and frequently in dermatology for cutaneous and/or arthritic psoriasis. Toxicities due to MTX overdosage are mainly cutaneous, hepatic and hematologic. Herein, we report a case of MTX overdosage presenting as an erosive and an inflammatory flare of preexisting psoriatic plaques and with new palmar lesions. PATIENTS AND METHODS: A 51-year-old male with a 6-year history of plaque psoriasis resistant to topical corticosteroids was started for the first time on MTX 20mg weekly...
September 13, 2017: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/28917472/-two-step-phototherapy-for-treatment-resistant-psoriasis-on-the-lower-extremities
#8
Caleb Jeon, Mio Nakamura
No abstract text is available yet for this article.
October 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28917454/a-phase-2a-open-label-pilot-study-of-the-galectin-3-inhibitor-gr-md-02-for-the-treatment-of-moderate-to-severe-plaque-psoriasis
#9
Simon Ritchie, Danielle Neal, Harold Shlevin, Adam Allgood, Peter Traber
No abstract text is available yet for this article.
October 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28917384/serious-infections-among-a-large-cohort-of-subjects-with-systemically-treated-psoriasis
#10
Allison S Dobry, Charles P Quesenberry, G Thomas Ray, Jamie L Geier, Maryam M Asgari
BACKGROUND: Biologic therapy is effective for treatment of moderate-to-severe psoriasis but may be associated with an increased risk for serious infection. OBJECTIVE: To estimate the serious infection rate among patients with psoriasis treated with biologic as compared with nonbiologic systemic agents within a community-based health care delivery setting. METHODS: We identified 5889 adult Kaiser Permanente Northern California health plan members with psoriasis who had ever been treated with systemic therapies and calculated the incidence rates and 95% confidence intervals (CIs) for serious infections over 29,717 person-years of follow-up...
September 13, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28917383/efficacy-and-safety-of-ixekizumab-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-results-through-108%C3%A2-weeks-of-a-randomized-controlled-phase-3-clinical-trial-uncover-3
#11
Andrew Blauvelt, Melinda Gooderham, Lars Iversen, Susan Ball, Lu Zhang, Noah O Agada, Kristian Reich
BACKGROUND: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin 17A, is efficacious in treating moderate-to-severe plaque psoriasis through 60 weeks. OBJECTIVE: To evaluate the efficacy and safety of ixekizumab through 108 weeks of treatment in UNCOVER-3. METHODS: Patients (N = 1346) were randomized 2:2:2:1 to 80 mg ixekizumab every 2 or 4 weeks, 50 mg etanercept twice weekly, or placebo. At week 12, patients switched to ixekizumab every 4 weeks during a long-term extension (LTE) period...
September 13, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28917381/uncovering-burden-disparity-a-comparative-analysis-of-the-impact-of-moderate-to-severe-psoriasis-and-hidradenitis-suppurativa
#12
Iltefat H Hamzavi, Murali Sundaram, Cynthia Nicholson, Marko Zivkovic, Angela Parks-Miller, Jianyi Lee, Jingbo Yi, Yihua Gu, Martin M Okun, Arijit Ganguli, Steve R Arikian
BACKGROUND: Psoriasis and hidradenitis suppurativa (HS) exhibit distinct clinical features, but no studies have directly compared the health-related quality of life (HRQoL) in patients with moderate-to-severe manifestations of these conditions. OBJECTIVE: To determine which disease is associated with more severe HRQoL impairment. METHODS: Weighted averages of each of the following baseline HRQoL measures were determined and compared between HS and psoriasis populations from 5 clinical trials: Visual Analog Scale (VAS) for pain, Total Work Productivity Impairment, Dermatology Life Quality Index; EuroQOL 5D VAS, and Short Form-36 Health Survey...
September 13, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28914955/alcohol-related-mortality-in-patients-with-psoriasis-a-population-based-cohort-study
#13
Rosa Parisi, Roger T Webb, Matthew J Carr, Kieran J Moriarty, C Elise Kleyn, Christopher E M Griffiths, Darren M Ashcroft
Importance: People diagnosed with psoriasis have an increased risk of premature mortality, but the underlying reasons for this mortality gap are unclear. Objective: To investigate whether patients with psoriasis have an elevated risk of alcohol-related mortality. Design, Setting, and Participants: An incident cohort of patients with psoriasis aged 18 years and older was delineated for 1998 through 2014 using the Clinical Practice Research Datalink (CPRD) and linked to Hospital Episode Statistics (HES) and Office for National Statistics (ONS) mortality records...
September 15, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/28914203/phytomedicines-are-efficient-complementary-therapies-for-the-treatment-of-atopic-dermatitis-a-review-of-mechanistic-insight-and-recent-updates
#14
Mohamad Aidil Tumpang, Nor Amlizan Ramli, Zahid Hussain
BACKGROUND: Phytomedicines have been well-accepted alternative complementary therapies for the treatment of a wide range of acute and chronic skin inflammatory diseases including chronic herpes, prurigo, psoriasis, and atopic dermatitis (AD). Plethora of in vitro and in vivo studies have evidenced the therapeutic viability of phytomedicines, polyherbal formulations, plant-based materials and their decoctions for the treatment of mild-to-severe AD. OBJECTIVE: This review was aimed to summarize and critically discuss the convincing evidence for the therapeutic effectiveness of phytomedicines for the treatment of AD and explore their anti-AD efficacy...
September 13, 2017: Current Drug Targets
https://www.readbyqxmd.com/read/28912410/-psoriasis-and-psoriatic-arthritis-induced-by-nivolumab-in-a-patient-with-advanced-non-small-cell-lung-cancer
#15
Yasoo Sugiura, Hiroyuki Fujimoto, Munehiro Yamamoto, Hisashi Nomura, Toshinori Hashizume, Osamu Kawai, Norito Araki, Kotaro Kawakami, Hitoshi Sueki, Hisae Fusegawa, Yasuyuki Ohkubo, Etsuo Nemoto
BACKGROUND: Immune checkpoint-blocking antibodies may induce specific side effects known as immune-relatedad verse events. CASE PRESENTATION: A 66-year-oldman without any history of autoimmune disease was referredto our hospital for treatment of lung cancer in the right upper lobe. The tumor was diagnosed as Stage III A non-small-cell lung cancer by using bronchoscopic biopsy, computedtomography, andFDG -PET. After a single course of cisplatin andpemetrexed , the tumor size increasedremarkably andthe regimen was changedto nivolumab(3mg/kg every 2 weeks)...
September 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28911642/lactobacillus-pentosus-gmnl-77-inhibits-skin-lesions-in%C3%A2-imiquimod-induced-psoriasis-like-mice
#16
Yi-Hsing Chen, Chieh-Shan Wu, Ya-Husan Chao, Chi-Chen Lin, Hui-Yun Tsai, Yi-Rong Li, Yi-Zhen Chen, Wan-Hua Tsai, Yu-Kuo Chen
Psoriasis, which is regarded as a T-cell-mediated chronic inflammatory skin disease, is characterized by hyperproliferation and poor differentiation of epidermal keratinocytes. In this study, we aimed to determine the in vivo effect of a potentially probiotic strain, Lactobacillus pentosus GMNL-77, in imiquimod-induced epidermal hyperplasia and psoriasis-like skin inflammation in BALB/c mice. Oral administration of L. pentosus GMNL-77 significantly decreased erythematous scaling lesions. Real-time polymerase chain reaction showed that treatment with L...
July 2017: Journal of Food and Drug Analysis
https://www.readbyqxmd.com/read/28906089/alopecia-as-unique-clue-to-syphilis-in-a-patient
#17
Laura Atzori, Laura Mantovani, Roberta Satta, Caterina Ferreli
Alopecia is an uncommon manifestation of syphilis, simulating other common forms of hair-loss, but representing a crucial complaint for the patient, who might by converse have not noticed other signs and symptoms of the disease. Esthetic issues undervaluation might prolong illness, and postpone appropriate treatment. A 42-year-old patient, HIV negative, presented with a 2-month history of progressive generalized thinning of the hairs and small non-scarring irregular alopecia patches of the parietal-occipital areas of the scalp...
October 2017: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/28906051/effectiveness-and-safety-of-secukinumab-in-69-patients-with-moderate-to-severe-plaque-psoriasis-a-retrospective-multicenter-study
#18
J F Schwensen, A Clemmensen, C Sand, R Gniadecki, L Skov, C Zachariae, L Iversen, M Rasmussen, S F Thomsen
Secukinumab (anti-IL17A) is effective as treatment for moderate to severe plaque psoriasis, but real-life data on effectiveness and safety lack. We aimed to present real-life data of all Danish patients treated with secukinumab (n = 69). At baseline, before initiation of treatment with secukinumab 300 mg (47.8%) or off-label treatment with secukinumab 150 mg (52.2%), the median PASI score was 7.1. A total of 66.7% (34/51) and 52.9% (27/51) of patients still on secukinumab at week 12 achieved a PASI (Psoriasis Area and Severity Index)-50 and PASI-75 of 66...
September 14, 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/28905102/digestive-system-in-psoriasis-an-update
#19
REVIEW
Daniel Pietrzak, Aldona Pietrzak, Dorota Krasowska, Andrzej Borzęcki, Kinga Franciszkiewicz-Pietrzak, Beata Polkowska-Pruszyńska, Maja Baranowska, Kristian Reich
Psoriasis is a chronic inflammatory immune-mediated disorder associated and often coexisting with many other immune-related clinical conditions including those affecting the gastrointestinal tract. Data obtained from the reviewed literature suggest an association between psoriasis and pathologies of the oral cavity, both psoriasis-specific lesions, as well as non-specific, such as geographic tongue or fissured tongue. These findings show the importance of thorough examination of oral mucosa in psoriatic patients...
September 13, 2017: Archives of Dermatological Research
https://www.readbyqxmd.com/read/28904916/prevalence-of-metabolic-syndrome-in-psoriasis-and-levels-of-interleukin-6-and-tumor-necrosis-factor-%C3%AE-in-psoriasis-patients-with-metabolic-syndrome-indian-tertiary-care-hospital-study
#20
Surjit Singh, Sunil Dogra, Nusrat Shafiq, Anil Bhansali, Samir Malhotra
BACKGROUND: Psoriasis is a chronic inflammatory multisystem disease, found to be associated with metabolic syndrome (MS) and increased levels of cytokines. To evaluate the prevalence of MS in psoriasis and to determine the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in psoriasis patients with MS. METHODS: Observational study on 334 psoriasis patients and 230 controls. MS was diagnosed by the presence of three or more criteria of original, revised, and modified National Cholesterol Education Program's Adult Treatment Panel III (NCEP ATP III)...
July 2017: International Journal of Applied and Basic Medical Research
keyword
keyword
60126
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"